MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
He, Kai, Berz, David, Gadgeel, Shirish M., Iams, Wade T., Bruno, Debora S., Blakely, Collin M., Spira, Alexander I., Patel, Manish R., Waterhouse, David M., Richards, Donald A., Pham, Anthony, Jotte, Robert, Hong, David S., Garon, Edward B., Traynor, Anne, Olson, Peter, Latven, Lisa, Yan, Xiaohong, Shazer, Ronald, Leal, Ticiana A.
Published in Journal of thoracic oncology (01.07.2023)
Published in Journal of thoracic oncology (01.07.2023)
Get full text
Journal Article
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Msaouel, Pavlos, Sweis, Randy F., Bupathi, Manojkumar, Heath, Elisabeth, Goodman, Oscar B., Hoimes, Christopher J., Milowsky, Matthew I., Davis, Nancy, Kalebasty, Arash Rezazadeh, Picus, Joel, Shaffer, David, Mao, Shifeng, Adra, Nabil, Yorio, Jeffrey, Gandhi, Sunil, Grivas, Petros, Siefker-Radtke, Arlene, Yang, Rui, Latven, Lisa, Olson, Peter, Chin, Curtis D., Der-Torossian, Hirak, Mortazavi, Amir, Iyer, Gopa
Published in European urology oncology (01.08.2024)
Published in European urology oncology (01.08.2024)
Get full text
Journal Article